Celltrion presents Truxima’s results of phase 3 clinical trials in US forum - (The Investor via NewsPoints Desk)

  • Celltrion has unveiled Phase III results for its biosimilar Truxima at the annual meeting of the American Society of Hematology (ASH), reported The Investor.

  • According to the company, Truxima was not inferior in terms of efficacy and safety for patients suffering advanced follicular lymphoma, compared to its reference drug, Roche's Rituxan.

  • The overall survival rate four years after receiving Truxima and Rituxan treatment was estimated to be around 88% and 93.3% respectively. 

  • The biosimilar's progression-free survival rate was 60.9% and Rituxan's rate was 54.7%, while Truxima's time to progression was also similar to the original drug.

  • "The clinical trials were conducted among patients in European countries including Germany, Spain and Russia as well as Asian countries like Japan for 40 months," a Celltrion official said.

To read more NewsPoints articles, click here.